saridon
Commercial- Indications
- Pain, Headache
Company intelligence / Profile preview
Piramal Pharma Limited
Mumbai, Maharashtra, Indiapiramalcpd.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Piramal Pharma reported 14% YoY revenue growth for 9M FY25, primarily driven by high-teen growth in the CDMO business. EBITDA grew by 20% YoY for 9M FY25, supported by operating leverage, cost optimization initiatives and superior revenue mix[5].
- Therapeutic areas
- ImmunologyGastroenterologyOphthalmologyInfectious Diseases
- Modalities
- Inhalation anestheticsinjectable pain therapiesintrathecal treatmentsspecialty pharmaceuticals
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
AbbVie (joint venture)CSC partnership for distribution[3][4]
Beyond the preview
Go deeper on Piramal Pharma Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Piramal Pharma Limited.